1. Pink Sheet

Biopharma Dismayed US Supreme Court Declines To Take Up Case On Patent Eligibility

 
• By Brenda Sandburg

The Court denies a petition for review of American Axle and Manufacturing v. Neapco despite requests from the US government, BIO and former PTO director Kappos that it take up the case to  provide greater clarity on the types of inventions that may be patented.

Patent eligibility
The US Supreme Court denied a petition requesting review of a case involving patent eligibility. • Source: Shutterstock

The US Supreme Court dashed the hopes of the biopharma industry in declining to take up a case to further address what inventions are eligible to be patented.

The Biotechnology Innovation Organization and others have long sought a course correction to the court’s rulings on subject matter patentability. They thought the court might grant review of American Axle and Manufacturing Inc. v. Neapco Holdings LLC and reconsider the issue after the US Solicitor General advised it to do so. BIO and former US Patent and Trademark Director David Kappos also filed amicus briefs in support of the petition

More from Legal & IP

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.